This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insider Trading Alert - Sherwin-Williams Company And 4 Others Traded By Insiders

United Therapeutics Corporation (UTHR) - FREE Research Report

Causey Christopher who is Director at UTD THERAPEUTIC bought 3,450 shares at $32.50 per share for a total value of $146,250.00 on July 5, 2013. Following this transaction, the Director owned 3,416 shares meaning that the stake was boosted by 116.32% with the 3,450 share acquisition.

Jeffs Roger who is President & COO at UTD THERAPEUTIC bought 26,773 shares at $30.84 per share for a total value of $925,250.00 on July 5, 2013. Following this transaction, the President & COO owned 56,293 shares meaning that the stake was boosted by 54.07% with the 26,773 share acquisition.

Rothblatt Martine A who is CEO at UTD THERAPEUTIC bought 716,564 shares at $25.46 per share for a total value of $393,409.08 on July 5, 2013. Following this transaction, the CEO owned 712,981 shares meaning that the stake was boosted by 17295.78% with the 716,564 share acquisition.

The shares most recently traded at $67.97, down $0.17, or 0.25% since the insider transactions. Historical insider transactions for United Therapeutics Corporation go as follows:

  • 24-Week # shares sold: 7,666

The average volume for United Therapeutics Corporation has been 676,800 shares per day over the past 30 days. United Therapeutics Corporation has a market cap of $3.3 billion and is part of the health care sector and drugs industry. Shares are up 25.81% year to date as of the close of trading on Monday.

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. The company has a P/E ratio of 10.7. Currently there are 3 analysts that rate United Therapeutics Corporation a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UTHR - FREE

TheStreet Quant Ratings rates United Therapeutics Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full United Therapeutics Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs